Health Care Weekly: No Surprises Act Arbiters Dropped for Poor Performance; Hims to Sell Unapproved Wellness Peptides; Telehealth Firm’s GLP-1 Ads Misleading, FDA Says; Novartis Gene Therapies Face Probe over Tumors; Quest Diagnostics Settles Kickback Claims Involving New York Giants NFL Tickets
The Health Care Weekly is a timely analysis of competition developments, policy changes and other updates that may affect medical and pharmaceutical markets. In this...






